Zai Lab Limited

NASDAQ:ZLAB

Biotechnology

Healthcare
$22.11 +3.42%

+$0.61 today

Market cap
$2.49B
Beta
0.78
P/E (TTM)
-11.4
EPS (TTM)
-$0.16
52W Low $15.96High $41.20

Volume 1.04M

Average 0.87M

ZLAB Net Income

Bottom-line profit after all expenses, interest, and taxes.

Zai Lab LimitedNASDAQ: ZLAB

Net Income · Q2 FY2026 · quarter ended Jun 2026

Net income remains negative

Q2 FY2026 net income was -$50.83M, compared with -$40.73M a year earlier. Trailing-twelve-month net income was -$188.21M.

Context

  • Net income amounted to 38.1% of revenue in FY2025, down 26.3 pp from a year earlier.
  • Net income grew in size in 0 of the last 3 fiscal years.
  • FY2025 was the smallest annual figure in the 4 fiscal years shown.

What to watch

Whether net income reaches the consensus estimate from 7 analysts of -$213.54M (-21.6%) for the fiscal year ending Dec 2026, a slowdown from the +31.7% reported in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterJun 2026
-$50.83M+0.4% QoQ
Last fiscal yearDec 2025
-$175.54M+31.7% YoY
LTMJun 2026
-$188.21M+11.4% YoY
Net Income past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-24.8%-84.9%-60.1 pp
1 year+31.7%-21.6%-53.4 pp
3-year CAGR———
5-year CAGR——
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

Net Income history

USD · from the income statement

Latest · FY2025
(175.54M) USD
Year-over-year change
+31.7%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

Net Income vs competitors

How ZLAB compares with its peers on the latest reported figures

  • Peers report in different currencies, so net income is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +11.4% is the 2nd highest of 3, against a peer median of +507.1%.
  • Net income amounts to 41.9% of revenue for ZLAB, versus a peer median of 216.5%.
ZLAB Competitors
Net Income for ZLAB and competitors
Company Period LTM YoY 3-year CAGR% of revenue
HCMHUTCHMED (China) LimitedLTM Jun 2025$466.88M USD+1212.4%—77.5%
ANLAdlai Nortye Ltd.LTM Jun 2024-$54.07M USD——833.1%
ZLABZai Lab LimitedLTM Jun 2026-$188.21M USD+11.4%—41.9%
AAPGAscentage Pharma Group InternationalFY2025-CN¥1.21B CNY-198.2%—216.5%
Peer median (excluding ZLAB) —+507.1%—216.5%

Competitors are the stored peer set for ZLAB. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue144.31M215.04M266.72M398.99M460.16M
Cost of Revenue52.24M74.02M95.82M147.86M191.08M
Gross Profit92.07M141.02M170.9M251.13M269.08M
Gross Margin63.8%65.6%64.1%62.9%58.5%
Research & Development573.31M286.41M265.87M234.5M220.9M
Selling, General & Admin218.83M258.97M281.61M298.74M277.61M
Operating Expenses792.14M545.38M537.48M533.25M492.65M
Depreciation & Amortization6.49M8.23M9.03M11.86M15.01M
EBITDA(689.46M)(434.84M)(365.11M)(242.99M)(158.25M)
EBITDA Margin-477.8%-202.2%-136.9%-60.9%-34.4%
Operating Income(700.06M)(404.36M)(366.57M)(282.12M)(223.57M)
Operating Margin-485.1%-188.0%-137.4%-70.7%-48.6%
Interest Income2.19M14.58M39.8M37.11M33.05M
Interest Expense0002.25M5.21M
Other Income / Expenses(3.35M)(38.93M)31.95M25.01M45.11M
Income Before Tax(703.41M)(443.29M)(334.62M)(257.1M)(178.46M)
Pre-Tax Margin-487.4%-206.1%-125.5%-64.4%-38.8%
Income Tax Expense1.06M000(2.93M)
Net Income(704.47M)(443.29M)(334.62M)(257.1M)(175.54M)
Net Margin-488.2%-206.1%-125.5%-64.4%-38.1%
EPS (Basic)(75.80)(46.30)(34.60)(2.60)(1.60)
EPS (Diluted)(75.80)(46.30)(34.60)(2.60)(1.60)
Weighted Avg Shares9.3M9.58M9.66M98.95M109.53M
Weighted Avg Shares (Diluted)9.3M9.58M9.66M98.95M109.53M

Zai Lab Limited

NASDAQ:ZLAB

Intrinsic Alpha fair value

Locked

Current Price

$22.11

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.